Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer.
Fu M, Maresh EL, Helguera GF, Kiyohara M, Qin Y, Ashki N, Daniels-Wells TR, Aziz N, Gordon LK, Braun J, Elshimali Y, Soslow RA, Penichet ML, Goodglick L, Wadehra M.
Fu M, et al. Among authors: elshimali y.
Mol Cancer Ther. 2014 Apr;13(4):902-15. doi: 10.1158/1535-7163.MCT-13-0199. Epub 2014 Jan 21.
Mol Cancer Ther. 2014.
PMID: 24448822
Free PMC article.